Navigation Links
McGill, Quebec biotech firm partner for new bone-disease treatment
Date:3/5/2010

This release is available in French.

Dr. Marc McKee, of McGill's Faculty of Dentistry and the Department of Anatomy and Cell Biology, is collaborating closely with Enobia Pharma Inc, a Quebec biotech company, to develop innovative treatments for serious genetic bone diseases. McKee's research looks into the reasons why calcium-phosphate mineral fails to crystallize properly to form strong bones and teeth. While osteoporosis later in life is an example of bone density deficiency, this research applies to patients, especially children, who never properly mineralized their skeletons to begin with.

The field is known as biomineralization and it involves cutting-edge, nanotech investigation into the proteins, enzymes and other molecules that control the coupling of mineral ions (calcium and phosphate) to form nano-crystals within the bone structure. The treatment, enzyme replacement therapy to treat hypophosphatasia, is currently undergoing clinical testing in several countries including Canada. Hypophosphatasia is a rare and severe disorder resulting in poor bone mineralization. In infants, symptoms include respiratory insufficiency, failure to thrive and rickets.

Luckily, McKee explains that "Montreal is a world-leader in the biomineralization field, having attracted some of the top international specialists." His collaboration with private and public sector experts is enabling real progress to be made with stunning and heart-warming results for the victims of this terrible affliction. Although hypophosphatasia is thought to only affect one in 100,000 people, McKee says that "research in this area is not just about this disease we are opening doors to the development of treatments for all kinds of problems related to the crystallization of minerals in the body, including seemingly unrelated areas such cardiovascular diseases, arthritis and even kidney stones."

McKee's research program is a concrete example of how university researchers are working with private sector partners as an integral part of Canada's innovative knowledge economy, and the positive outcomes their collaborations can offer. McKee's research is funded in part by the Canadian Institutes of Health Research.


'/>"/>

Contact: William Raillant-Clark
william.raillant-clark@mcgill.ca
514-398-2189
McGill University
Source:Eurekalert

Related biology news :

1. Boost from McGill, Gates Foundation helps Africans control pharma research
2. MUHC and McGill scientists explain genetic disease first discovered in Quebec 24 years ago
3. How the public perceives biotech
4. Monsanto expands sponsorship for Peking-Yale Joint Agrobiotechnology Center
5. Biotech Co. founded by UCLA Scientists to be acquired by Astellas, Pharma Inc.
6. Workshops on biotechnology and water for science journalists
7. Oncolytics Biotech, Inc. announces publication of research
8. Genetic Engineering & Biotechnology News reports on advances in miRNA
9. Biotechnology needs 21st century patent system: Expert
10. Genetic Engineering & Biotechnology News reports on cancer biomarkers
11. Food biotechnology: real world challenges
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th ... in San Francisco, CA. The Summit brings together current and former FDA office bearers, ... and government officials from around the world to address key issues in device compliance, ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... implantation and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... and maternal age to IVF success. , After comparing the results from the ...
(Date:10/10/2017)... ... 10, 2017 , ... Dr. Bob Harman, founder and CEO of VetStem ... The event entitled “Stem Cells and Their Regenerative Powers,” was held ... Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
Breaking Biology Technology: